Ainos (NASDAQ:AIMD) Major Shareholder Carbon Nano Technology Taiwan Sells 41,000 Shares

Ainos, Inc. (NASDAQ:AIMD) major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $2.36, for a total transaction of $96,760.00. Following the transaction, the insider directly owned 948,925 shares in the company, valued at approximately $2,239,463. The trade was a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ainos Price Performance

Shares of AIMD opened at $2.56 on Thursday. The firm has a market cap of $21.81 million, a PE ratio of -0.89 and a beta of 2.29. The firm’s 50 day moving average price is $1.67 and its 200 day moving average price is $1.83. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55. Ainos, Inc. has a twelve month low of $1.26 and a twelve month high of $4.50.

Ainos (NASDAQ:AIMD) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Institutional Investors Weigh In On Ainos

Hedge funds and other institutional investors have recently modified their holdings of the stock. DRW Securities LLC grew its stake in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after acquiring an additional 48,439 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after acquiring an additional 7,700 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Ainos in the third quarter worth $80,000. Finally, Mariner LLC acquired a new stake in shares of Ainos in the fourth quarter worth $37,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.